Torben Lund-Hansen
Chief Tech/Sci/R&D Officer chez Y-MABS THERAPEUTICS, INC.
Fortune : 1 M $ au 31/03/2024
Profil
Torben Lund-Hansen is currently the Chief Technology Officer & Senior Vice President at Y-mAbs Therapeutics, Inc. He previously worked as the Director-Process Development at Medarex, Inc., Senior Vice President-Technical Operations at Genmab A, Senior Vice President-Technical Operations at Genmab, Inc., and Principal at Novo Nordisk, Inc. He was also the President & Treasurer at Genmab MN, Inc. from 2008 to 2009.
From 2009 to 2016, he owned Lund-Hansen Consulting ApS.
Dr. Lund-Hansen holds graduate and doctorate degrees from the University of Copenhagen.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/01/2024 | 81 262 ( 0,19% ) | 1 M $ | 31/03/2024 |
Postes actifs de Torben Lund-Hansen
| Sociétés | Poste | Début |
|---|---|---|
| Y-MABS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2016 |
Anciens postes connus de Torben Lund-Hansen
| Sociétés | Poste | Fin |
|---|---|---|
| Lund-Hansen Consulting ApS | Corporate Officer/Principal | 01/01/2016 |
Genmab, Inc.
 Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Genmab, Inc. creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. It also offers products for cancer and autoimmune disorders. The company is headquartered in Princeton, NJ. | Chief Operating Officer | 01/01/2009 |
| Genmab MN, Inc. | President | 01/01/2009 |
| GENMAB A/S | Corporate Officer/Principal | - |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Corporate Officer/Principal | - |
Formation de Torben Lund-Hansen
| University of Copenhagen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GENMAB A/S | Health Technology |
| Y-MABS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
Genmab, Inc.
Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Genmab, Inc. creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. It also offers products for cancer and autoimmune disorders. The company is headquartered in Princeton, NJ. | Commercial Services |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
| Genmab MN, Inc. | |
| Lund-Hansen Consulting ApS |
